These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 28765013)
1. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors. Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013 [TBL] [Abstract][Full Text] [Related]
2. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors. Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors. Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents. Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening. Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors. Tian Y; Xie Z; Liao C Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129 [TBL] [Abstract][Full Text] [Related]
7. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities. Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors. Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912 [TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008 [TBL] [Abstract][Full Text] [Related]
12. Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids. Sodji QH; Kornacki JR; McDonald JF; Mrksich M; Oyelere AK Eur J Med Chem; 2015; 96():340-59. PubMed ID: 25899338 [TBL] [Abstract][Full Text] [Related]
13. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity. Xie R; Li Y; Tang P; Yuan Q Bioorg Med Chem Lett; 2017 Sep; 27(18):4415-4420. PubMed ID: 28818449 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors. Wu J; Wang X; Yao Y; Du N; Duan L; Gong P Bioorg Chem; 2024 Oct; 151():107556. PubMed ID: 39068717 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Liu R; Wang J; Tang W; Fang H Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. Cheng C; Yun F; He J; Ullah S; Yuan Q Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors. Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186 [TBL] [Abstract][Full Text] [Related]
18. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors. Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326 [TBL] [Abstract][Full Text] [Related]
20. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors. Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]